Incapta Inc
Change company Symbol lookup
Select an option...
INCT Incapta Inc
BML-J Bank of America Corp
PEP PepsiCo Inc
AGNC Agnc Investment Corp
ACM AECOM
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
Go

Communication Services : Entertainment |
Company profile

InCapta, Inc. is a media holding company. The Company is focused on the radio, television, movie production and television productions to use on online Cloud television and radio. It is developing its online movie channel, a 24 hour a day streaming Internet television station, and its online news and video news bureau in association with Leading Edge Radio Network and Mancuso Martin Productions. The Company operates two cloud television networks: World Drone Recreation Aviators and Leading Edge Radio Network. Its network develops its own channel content. It is also involved in pre-production of two full-length movies; developing a weekly half hour television show; and producing radio talk show with LeadingEdgeRadio.com.

Closing Price
$0.0001
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0002
Day's Low
0.0001
Volume
(Light)
Volume:
5,520,151

10-day average volume:
26,185,466
5,520,151

Supernus to Participate in Annual Piper Sandler Healthcare Conference

10:00 pm ET November 18, 2020 (Globe Newswire) Print

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will participate in a fireside chat as part of the Piper Sandler 32 Annual Virtual Healthcare Conference, being held December 1-3, 2020. The Company will also host investor meetings on Thursday, December 3, 2020.

The pre-recorded fireside chat can be accessed beginning November 23, 2020 by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of this fireside chat will be available for 60 days on the Company's website after the conference.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations ("on-off" episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.

See full Prescribing Information for our products here: Trokendi XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.

All trademarks are the property of their respective owners.

CONTACTS:

Jack A. Khattar, President and CEO

Jim Kelly, EVP & Chief Financial Officer

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo

Westwicke, an ICR Company

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg

https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.